Intravitreous self adaptive stent

• US 9,539,087 B2
• Filed: 04/28/2010
• Issued: 01/10/2017
• Est. Priority Date: 04/28/2010
• Status: Expired due to Fees

• Current Assignee: Empire Technology Development LLC (Allied Inventors Management, LLC)
• Original Assignee: Empire Technology Development LLC (Allied Inventors Management, LLC)
• Inventors: Dai, Rongping
• Primary Examiner(s): Matthews, Howie
• Application Number:
  US13/123,440
• Publication Number:
  US 20120035738A1
• Time in Patent Office: 2,449 Days
• Field of Search: 623/4.1, 623 663- 664, 623/23.64, 623 2367- 237
• US Class Current: 1/1
• CPC Class Codes: A61F 2/14 Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
• CPC Class Codes: A61F 2/82 Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents stent-grafts for tubular structures of the body other than blood vessels A61F2/04; stent-grafts for blood vessels A61F2/07; instruments specially adapted for placement or removal of stents or stent-grafts A61F2/95; for closing wounds, or holding wounds closed A61B17/04 - A61B17/115; dilators A61M29/00
• CPC Class Codes: A61F 2/844 folded prior to deployment
• CPC Class Codes: A61F 2/848 having means for fixation to the vessel wall, e.g. barbs
• CPC Class Codes: A61F 2/92 Stents in the form of a rolled-up sheet expanding after insertion into the vessel , e.g. with a spiral shape in cross-section
• CPC Class Codes: A61F 2210/0014 using shape memory or superelastic materials, e.g. nitinol
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61F 9/00 Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand caps with means for protecting the eyes A42B1/018; visors for helmets A42B3/22; retractors A61B17/02; manipulators specially adapted for use in surgery A61B34/70; appliances to aid invalids to move about A61H3/00; exercisers for the eyes A61H5/00; eye baths A61H35/02; sunglasses or goggles having the same features as spectacles G02C
• CPC Class Codes: A61F 9/007 Methods or devices for eye surgery
• CPC Class Codes: A61L 31/022 Metals or alloys
• CPC Class Codes: A61L 31/06 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds A61L31/041 takes precedence
• CPC Class Codes: A61L 31/14 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence

Abstract

Disclosed herein are devices, methods and kits for a stent for treating an eye, comprising a flexible material, wherein the stent is self adaptive to a dimension of a vitreous cavity in the eye.

Claims

1. A stent for an eye, comprising:

a flexible material,

wherein the stent is of an annular shape at a body temperature, and has a distal and a proximal end, and is self-adaptive to a dimension of a vitreous cavity in the eye by a self-adaptive zone which is located at the distal end and has either;

a single opening which divides the annular shape of the stent along its height;

or

a fold which projects radially inwards and extends along the height of the annular shape of the stent;

and wherein the self-adaptive zone has a width in a range of about 1-8 mm; and

further wherein the stent has a height of about 5 mm.

2. The stent of claim 1, wherein the flexible material is selected from the group consisting of silicon, styrene, polypropylene, polyurethane, poly (caprolactone-β

-ethylene oxide), poly (L-lactide-co-glycolide), and polytetrafluoroethylene.

3. The stent of claim 1, wherein the flexible material is an aliphatic ester C1-C50 of acrylic acid or a methacrylic acid ester of polyethyleneoxide.

4. The stent of claim 3, wherein the aliphatic ester C1-C50 of acrylic acid is an aliphatic ester C1-C50 of methacrylic acid.

5. The stent of claim 3, wherein the aliphatic ester C1-C50 of acrylic acid is selected from the group consisting of butyl acrylate, polyarcylic acid, poly(methyl methacrylimide), pentafluoropropylacrylate, polyethylene glycol methacrylate, polyethyleneglycol monomethylether methacrylate, methylmethacrylate, poly(methyl methacrylate), isobornyl methacrylate, isobutyl methacrylate, perfluoroacetylmethacrylate, tertiary butylmethacrylate, phenylethylmethacrylate, hydroxyethyl methacrylate, glycerol methacrylate, and heptadecylfluorodecyl-methacrylate.

6. The stent of claim 3, wherein the methacrylic acid ester of polyethyleneoxide is polyethyleneglycol dimethacrylate, polyethyleneglycol methacrylate or polyethyleneglycol acrylate.

7. The stent of claim 1, wherein the flexible material is a shape memory substance.

8. The stent of claim 7, wherein the shape memory substance is a titanium-nickel (Ti—

Ni) based shape memory alloy or polymer thereof.

9. The stent of claim 8, wherein the Ti—

Ni based shape memory alloy comprises Ti at about 43.5 wt % to about 52 wt % and Ni at about 48 wt % to about 56.5 wt %.

10. The stent of claim 8, wherein the Ti—

Ni based shape memory alloy is of an annular shape at a body temperature and a folded shape at room temperature.

11. The stent of claim 1, wherein the flexible material is a biodegradable material.

12. The stent of claim 11, wherein the biodegradable material is poly (caprolactone-β

-ethylene oxide) or poly (L-lactide-co-glycolide).

13. The stent of claim 1, wherein the annular shape has a diameter which approximates a diameter of the vitreous cavity of the eye.

14. The stent of claim 1, further comprising one or more projections for fixing the stent in the eye.

15. The stent of claim 1, further comprising a therapeutic agent.

18. The stent of claim 1, wherein the flexible material is a non-biodegradable material.

19. The stent of claim 18, wherein the non-biodegradable material is a Ti—

Ni based shape memory alloy, poly(acrylic acid), and poly(methyl methacrylimide).

16. A method of treating an ocular disease in a subject, comprising:

implanting a stent in an eye of the subject wherein the stent comprises a flexible material,

wherein the stent is of an annular shape at a body temperature, and has a distal and a proximal end, and is self-adaptive to a dimension of a vitreous cavity in the eye by a self-adaptive zone which is located at the distal end and has either;

a single opening which divides the annular shape of the stent along its height;

or

a fold which projects radially inwards and extends along the height of the annular shape of the stent;

and wherein the self-adaptive zone has a width in a range of about 1-8 mm; and

further wherein the stent has a height of about 5 mm.

17. The method of claim 16, wherein the ocular disease is vitreoretinopathy.